Navigation Links
Once Monthly Dosing: How Much of a Competitive Advantage is it? Rheumatologists Provide Insight in the Baseline Report of LaunchTrends(TM): SIMPONI(TM)
Date:6/4/2009

EXTON, Pa., June 4 /PRNewswire/ -- BioTrends Research Group, Inc. announces the release of the baseline LaunchTrends(TM): SIMPONI report. The survey was completed by U.S. Rheumatologists in May 2009, just days after the FDA announced approval for SIMPONI (golimumab).

Once monthly dosing seems to be playing well, according to the Rheumatologists in the study who anticipate relatively quick uptake of SIMPONI. 84% of the Rheumatologists surveyed report that they intend to use SIMPONI within the next six months, and a fair proportion intend to incorporate SIMPONI into their armamentarium right away. The majority of RA patients likely to be placed on SIMPONI are expected to be switched from current biologic agents, primarily impacting use of Enbrel, Humira and Remicade. The main advantages that clinicians perceive for SIMPONI compared to currently available agents are the monthly dosing regimen and self injection. On the downside, SIMPONI is a new addition to an already crowded market of TNF agents with a similar mechanism of action and a lack of any clear clinical differentiation. Concern was also expressed about the lack of radiographic data at the time of launch to support the drug's ability to slow the progression of disease.

Adding to the competitive environment, the FDA approved UCB's CIMZIA(R) (certolizumab) for Rheumatoid Arthritis on May 14th, bringing yet another once monthly TNF agent into the mix. In addition to the recent launches of SIMPONI and CIMZIA there is significant interest among Rheumatologists in Roche's ACTEMRA(R) (tocilizumab), an IL-6 blocker currently under review with the FDA. When presented with all three products, interest was highest for ACTEMRA.

LaunchTrends(TM) measures launch effectiveness of new products from FDA approval through six months post launch. The next wave of this report, measuring uptake at one month post launch, will be
'/>"/>

SOURCE BioTrends Research Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Nuvilex, Inc. Announces Monthly Investor Conference Call
2. SIMPONI(TM) (golimumab) Receives FDA Approval as First Once-Monthly Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
3. National Council on Disability Monthly Bulletin for February, 2009
4. U.S. Labor Department to begin new monthly data series on people with disabilities from Current Population Survey on Feb. 6
5. Medical City Hospital Named by Texas Monthly as One of the Top Ten Best Companies to Work for in Texas
6. National Council on Disability Monthly Bulletin for November 2008
7. Renowned Thoracic Surgeon Recognized as Top Doctor by Peers in Annual New Jersey Monthly Magazine Survey
8. National Council on Disability Monthly Bulletin for October 2008
9. National Council on Disability Monthly Bulletin for June, 2008
10. National Council on Disability Monthly Bulletin for March 2008
11. National Council on Disability Monthly Bulletin for February, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... (PRWEB) , ... July 28, 2015 , ... Bipolar disorder ... times a day to a few times a year. The World Health Organization (WHO) ... by the National Institute of Mental Health reveals that the United States has the ...
(Date:7/28/2015)... ... July 28, 2015 , ... A new Taiwanese study ... they are in the general population. Surviving Mesothelioma has just posted an article ... Researchers at Taiwan’s National Health Research Institutes and three Taiwanese universities evaluated the ...
(Date:7/28/2015)... (PRWEB) , ... July 28, 2015 , ... A new ... May Easy Fibromyalgia, Study Says " sheds light on a possible new treatment option ... of two months of regular HBOT sessions, at least five per week, patients experienced ...
(Date:7/28/2015)... ... July 28, 2015 , ... There has been much discussion in ... bridges and railroads, often overlooked is the over 740,000 miles of municipal sewer ... into sewage treatment facilities. According to the American Society of Civil Engineers , ...
(Date:7/28/2015)... ... July 28, 2015 , ... Please join us for the 5th Annual Step for Hope ... at Gary Avenue and Lies Road in Carol Stream. All are welcome. , Now ... provide education and help to support individuals and families affected by a brain aneurysm. ...
Breaking Medicine News(10 mins):Health News:"I Am Not I" Music Video Raises Bipolar Disorder Awareness 2Health News:New Findings Suggest Mesothelioma is Not the Only Cancer Threat for Shipbreakers, According to Surviving Mesothelioma 2Health News:Recovery Specialists Discuss How Oxygen Therapy Can Ease Fibromyalgia 2Health News:Recovery Specialists Discuss How Oxygen Therapy Can Ease Fibromyalgia 3Health News:With an Infrastructure Spending Bill on the Horizon, RestorationEze Discusses the Impact an Aging Sewer System is Having on Homeowners 2Health News:With an Infrastructure Spending Bill on the Horizon, RestorationEze Discusses the Impact an Aging Sewer System is Having on Homeowners 3Health News:5th Annual Step for Hope 5K Run/Walk Event in Carol Stream, IL to Benefit Renowned Brain Aneurysm Foundation 2
... Rebuild Schools and Clinics, LOS ANGELES, May 14 ... relief agency,today announced that it is responding with aid ... earthquake has mobilized relief agencies from,around the world and ... the call., The Chinese Army is taking the ...
... Offers Tips to Help Make Healthy Choices on the ... Swimsuit season is right around the,corner and for many ... though, cutting back on calories and finding time to ... CareerBuilder.com survey reports,that 45 percent of workers have gained ...
... by Johns Hopkins doctors has fine-tuned the dosage and ... patients with strokes caused by bleeding within the brain. ... Stroke Conference in Nice, France, has been shown to ... typically lethal subset of stroke. , "We,ve gone from ...
... children can be picky eaters,spooked by strong flavors or ... the taste of the pickiest eaters. But just because ... family can,t,enjoy something with more zip. To help parents ... without spending all night in the kitchen,Mealtime.org has devised ...
... Stable Treatment for Hemophilia With ... Patients, PRINCETON, N.J., May 13 Novo ... Administration (FDA) has approved,NovoSeven(R) RT (Coagulation Factor VIIa ... recombinant product available,for the treatment of bleeding episodes ...
... Ill., May 13 Z Trim Holdings, Inc.,(Amex: ... statements,for the fiscal year ended December 31, 2007 contained ... accounting,firm, Blackman Kallick LLP. This announcement is being made ... which requires separate disclosure,of receipt of an audit opinion ...
Cached Medicine News:Health News:Forty-Five Percent of U.S. Employees Have Gained Weight at Their Current Jobs, CareerBuilder.com Study Finds 2Health News:Forty-Five Percent of U.S. Employees Have Gained Weight at Their Current Jobs, CareerBuilder.com Study Finds 3Health News:Forty-Five Percent of U.S. Employees Have Gained Weight at Their Current Jobs, CareerBuilder.com Study Finds 4Health News:Researchers fine-tune clot-busting treatment for bleeding in brain 2Health News:Personalized Plates for Picky Palates: Moms can Satisfy all With One Recipe, Four Ways 2Health News:FDA Approves NOVO NORDISK's NovoSeven(R) RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) for Hemophilia Patients With Inhibitors 2Health News:FDA Approves NOVO NORDISK's NovoSeven(R) RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) for Hemophilia Patients With Inhibitors 3Health News:FDA Approves NOVO NORDISK's NovoSeven(R) RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) for Hemophilia Patients With Inhibitors 4Health News:Z Trim Holdings, Inc. Audit Report Contains 'Going Concern' Qualification 2
(Date:7/28/2015)... July 28, 2015  ULURU Inc. (OTCQB: ULUR) announced today ... the appointment of Bradley J. Sacks to the ... of Directors has determined that the 2015 Annual Meeting of ... at 10:00 a.m., Central Daylight Time at the offices of ... 75001. In accordance with the provisions of ...
(Date:7/28/2015)... 28, 2015  Alere Inc. (NYSE: ALR ), ... it will release its financial results for the second ... a conference call beginning at 8:30 a.m. ET on ... provide business updates. The conference call ... of Alere,s website, or accessed directly through the following ...
(Date:7/28/2015)... , July 28, 2015  Cepheid (Nasdaq: ... flexible and portable clinical molecular diagnostic system designed ... Care market.  At just 9 inches tall, and ... run the same high quality PCR-based Xpert® cartridges ... highly accurate clinical molecular diagnostic tests to be ...
Breaking Medicine Technology:ULURU Inc. Announces The Schedule For The 2015 Annual Meeting Of Stockholders And The Appointment Of Bradley J. Sacks To The Board Of Directors 2ULURU Inc. Announces The Schedule For The 2015 Annual Meeting Of Stockholders And The Appointment Of Bradley J. Sacks To The Board Of Directors 3Alere to Report Second Quarter 2015 Financial Results on August 4, 2015 2World's First "Go-Anywhere" Molecular Diagnostic System Unveiled at AACC 2World's First "Go-Anywhere" Molecular Diagnostic System Unveiled at AACC 3World's First "Go-Anywhere" Molecular Diagnostic System Unveiled at AACC 4
... FRANCISCO, Calif., Nov. 27 Raven,biotechnologies, inc., a privately ... (MAbs) for cancer, today announced it,is continuing to enroll ... of its Phase 1/2a trial for patients with cancers ... RAAG12 is a glycotope (sugar structure) that is widely ...
... Kinex Pharmaceuticals LLC,announced today that their drug KX2-391 ... is entitled "A combined rising single-dose (RSD) and,rising ... tolerability,and pharmacokinetics of KX2-391 in patients with advanced ... belongs to an emerging,new family of targeted cancer ...
Cached Medicine Technology:Raven Announces Continued Enrollment of Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas 2Raven Announces Continued Enrollment of Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas 3First Patient Dosed with KX2-391 in Phase 1 Clinical Trial 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: